

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Identifying the barriers and facilitators to culturally responsive HIV and PrEP screening for racial, ethnic, sexual, and gender minoritized patients: A scoping review protocol

Julia Xavier^{1¶}, Patrick G. Corr^{1*¶}, Maranda C. Ward^{1¶}, Nikhil Kalita^{2¶}, Paige McDonald^{1¶}

¹The George Washington University School of Medicine and Health Sciences, Washington, D.C., USA

²The George Washington University Milken School of Public Health, Washington, D.C., USA

*Corresponding Author, email: pcorr@gwu.edu (PGC); 2600 Virginia Avenue NW, Suite 300, Washington DC, 20037

24 **Abstract**

25 **Introduction:** While mainstream messaging about human immunodeficiency virus (HIV)
26 disparities continues to highlight individual risk-taking behavior among historically marginalized
27 groups, including racial, ethnic, sexual, and gender minoritized patients, the effect of structural
28 factors and social determinants of health (SDOH) on morbidity and mortality remain
29 underestimated. Systemic barriers, including a failure of adequate and acceptable screening, play
30 a significant role in the disparate rates of disease. Primary care practitioner (PCP) competency in
31 culturally responsive screening practices is key to reducing the impact of structural factors on
32 HIV rates and outcomes. To address this issue, a scoping review will be performed to inform the
33 development of a training series and social marketing campaign to improve the competency of
34 PCPs in this area.

35 **Objectives:** This scoping review aims to analyze what recent literature identify as facilitators
36 and barriers of culturally responsive HIV and pre-exposure prophylaxis (PrEP) screening
37 practices for historically marginalized populations, specifically racial, ethnic, sexual, and gender
38 minoritized groups. A secondary aim is to identify themes and gaps in the literature to help guide
39 future opportunities for research.

40 **Methods:** This scoping review will be performed following the framework set forth by Arksey
41 and O'Malley and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
42 extension for scoping reviews (PRISMA-ScR). Relevant studies between the years 2019-2022
43 will be identified using a rigorous search strategy across four databases: MEDLINE (via
44 PubMed), Scopus, Cochrane (CENTRAL; via Wiley), and CINAHL (via EBSCO), using
45 Boolean and Medical Subject Headings (MeSH) search terms. Studies will be uploaded to the

46 data extraction tool Covidence to remove duplicates and perform a title/abstract screening,
47 followed by a full-text screening and data extraction.

48 **Results:** Data will be extracted and analyzed for themes related to culturally responsive HIV and
49 PrEP screening practices in clinical encounters with the identified target populations. Results
50 will be reported according to PRISMA-ScR guidelines.

51 **Discussion:** To our knowledge, this is the first study to use scoping methods to investigate
52 barriers and facilitators to culturally responsive HIV and PrEP screening practices for racial,
53 ethnic, sexual, and gender minoritized populations. The limitations of this study include the
54 analysis restrictions of a scoping review and the timeframe of this review. We anticipate that this
55 study's findings will interest PCPs, public health professionals, community activists, patient
56 populations, and researchers interested in culturally responsive care. The results of this scoping
57 review will inform a practitioner-level intervention that will support culturally sensitive quality
58 improvement of HIV-related prevention and care for patients from minoritized groups.
59 Additionally, the themes and gaps found during analysis will guide future avenues of research
60 related to this topic.

61 **Keywords:** culturally responsive communication, primary care practitioners, quality of
62 healthcare, historically marginalized populations

63

64 **Introduction**

65 Central to the effective care of historically excluded communities is an appreciation for
66 cultural responsiveness, sometimes called cultural competence, among primary care practitioners
67 (PCPs). In the context of primary care, culturally responsive communication refers to a PCP's
68 ability to engage with patients “based on views of culturally diverse patients rather than the
69 views of health care professionals.”¹ Cultural responsiveness centers unique patient experiences
70 and understandings of health and illness, recognizes the individual biases that clinicians may
71 hold, and seeks to work productively with patients who are not typically represented or valued in
72 the Western understandings of care. At an organizational level, cultural responsiveness includes
73 valuing diversity within the community; institutionalizing cultural awareness; and adapting to
74 best serve the community by creating policies, systems, administrations, and protocols that allow
75 for effective cross-cultural interactions.² This type of approach allows healthcare practitioners to
76 work consciously and effectively toward cultivating health equity for historically marginalized
77 groups.

78 Human immunodeficiency virus (HIV) and coronavirus disease 2019 (COVID-19), for
79 instance, are two preventable, communicable illnesses with significant burdens of disease that
80 are highly stigmatized and disproportionately affect racial, ethnic, sexual and gender minoritized
81 groups, hereafter referred to as “minoritized groups”. Structural factors including systemic
82 oppression and social determinants of health (SDOH) play a significant role in the differential
83 health outcomes of these diseases but may receive less attention than a patient's personal factors
84 and choices. In the landscape of these existing disparities, patients from minoritized groups are
85 disproportionately harmed by the underutilization of culturally responsive screening practices in
86 the primary care setting. Further, while shifts in research and funding priorities allowed for swift

87 and large-scale responses to COVID-19, the recent pandemic has drawn much needed resources
88 and attention away from HIV prevention and care, exacerbating the disparities of this illness and
89 creating missed opportunities to address both diseases.³

90 To address these issues, the study team is undertaking a project to train and build the
91 capacity of PCPs to routinize culturally responsive and nonjudgmental communication about
92 screening and testing for minoritized groups regarding HIV and COVID-19. By providing
93 regular, culturally responsive screening and education related to COVID-19 and HIV, PCPs can
94 begin to bridge the divide in health disparities impacting minoritized communities. This project
95 is multifaceted and includes data collection through scoping literature reviews and qualitative
96 interviews that concern the experiences and beliefs of minoritized groups regarding HIV and
97 COVID-19. These data will be used to inform and validate: a) a training series for PCPs about
98 HIV testing, pre-exposure prophylaxis (PrEP) screening, and COVID-19 vaccine screening; b) a
99 social marketing campaign for PCPs and by PCPs to encourage routinizing culturally responsive
100 conversations about testing, screening, and prevention; and c) a culminating white paper on
101 policy recommendations to improve HIV screening guidelines and to better implement existing
102 PrEP and COVID-19 guidelines. This article discusses the protocol that will be used to perform a
103 scoping review focused on HIV and PrEP screening, specifically.

104 **Background**

105 Despite progress over the last forty years in reducing HIV transmission, morbidity, and
106 mortality, nearly 1.2 million people are still living with HIV in the United States according to
107 most recent data.⁴ Among those living with and becoming newly infected with HIV, minoritized
108 groups deal with a greater burden of disease. For example, male-to-male sexual encounters made
109 up more than two-thirds of HIV diagnoses in 2020,⁴ and a 2021 CDC special report found that 4

110 in 10 transgender women in major cities are living with HIV.⁵ Similarly, although Black
111 Americans made up only 13.6% of the U.S. population in 2020, they represented more than 40%
112 of HIV diagnoses that year.^{4,6} The same year, Hispanic or Latinx individuals made up 27% of
113 HIV diagnoses, despite making up less than 19% of the U.S. population.^{4,6} Despite mainstream
114 messaging that still claims these populations are more often engaged in high-risk behaviors,
115 research data support that structural and systemic issues like socioeconomic status, housing, the
116 physical environment, and unequal access to preventative care have contributed to these stark
117 health disparities more significantly than individual risk behaviors.³

118 Among those living with HIV, more than 1 in 10 are not aware of their HIV status
119 because they have not been tested.⁷ Without an understanding of their HIV status and risk, these
120 patients may be unable to start pre- or post-exposure prophylaxis (PrEP or PEP) or the
121 appropriate therapies to suppress their viral load. Following the current trajectory, without
122 further intervention, close to 400,000 more people will be diagnosed with HIV by 2030.⁸ For
123 these reasons, HIV prevention and diagnosis are central to the U.S. Department of Health and
124 Human Services (HHS) *Ending the HIV Epidemic in the U.S.* plan for the next decade. The HHS
125 plan aims to reduce new HIV infections by over 90% by 2030.⁸ PrEP coverage, a key indicator
126 of *Ending the HIV Epidemic in the U.S.*, shows a distinct failing. Current US Public Health
127 Service PrEP clinical practice guidelines recommend that all sexually active patients receive
128 information regarding PrEP and that those at substantial risk should be prescribed either daily
129 oral PrEP or a recently approved intramuscular injection every two months.⁹ Despite this, in
130 2020, only 1 in 4 people in the U.S. and Puerto Rico who had indications for PrEP were
131 receiving PrEP.¹⁰ Among these individuals, the aforementioned racial and ethnic disparities

132 persist: while 66% of indicated White patients were covered, only 9% of indicated Black patients
133 and only 16% of indicated Hispanic or Latinx patients were receiving PrEP.¹⁰

134 Moreover, while the Centers for Disease Control and Prevention (CDC) has
135 recommended for more than 15 years that routine healthcare include opt-out HIV screening
136 (defined as performing an HIV test) at least once for patients between the ages of 13 and 64, and
137 at least annually for patients with risk factors,¹¹ qualitative data from other arms of this study
138 have already indicated that minoritized patients not only feel targeted and disrespected by HIV
139 testing without context, but they report concerns that opt-out testing is or will be performed
140 without their consent. These feelings exacerbate the mistrust that historically exploited groups
141 have of healthcare practitioners and institutions. Even without this barrier, testing rates have not
142 increased ubiquitously throughout the healthcare system. A 2020 Morbidity and Mortality
143 Weekly Report by the CDC reported that HIV testing has been increasing in community health
144 centers and emergency department settings, but not in physician offices.¹²

145 The above metrics support the idea that a chronic underutilization of HIV screening and
146 prevention practices, especially in the primary care setting, misses a crucial health promotion
147 opportunity, and disproportionately harms members of historically marginalized groups due to
148 the systemic barriers that exist within healthcare and societal institutions. It is the responsibility
149 of PCPs to understand these barriers and to identify the impacts of structural racism on the poor
150 outcomes and delayed identification of HIV in minoritized groups so they may prioritize
151 culturally responsive communication with these patient populations. The definition of HIV
152 screening must expand to include these conversations about HIV and PrEP to conscientiously
153 serve historically marginalized patients. Moving forward, we use the term “screening” to indicate

154 screening conversations and communication practices among PCPs that facilitate informed HIV
155 testing and connection to PrEP.

156 To begin meeting these aims and the study goals outlined above, we will conduct a
157 scoping review to assess existing literature for insights about this topic. To our knowledge, there
158 has not yet been a scoping review regarding this subject and the target patient populations. A
159 preliminary search of databases identified no ongoing or existing systematic/scoping reviews on
160 this topic. Therefore, the scoping review will be conducted with two specific purposes. Firstly, to
161 inform our understanding of the factors which influence culturally responsive HIV and PrEP
162 screening conversations for historically marginalized populations. The results of this review will
163 inform the design of a training series and social marketing campaign targeted at PCPs. Secondly,
164 the review will identify themes and gaps in the current literature to guide future research
165 opportunities in this field.

166 **Timeline**

167 This scoping review was designed in October 2022, reviewed with members of the
168 research team, and shared with university reference librarians for initial feedback. Data
169 extraction and analysis will begin in late January 2023 and continue through March 2023. We
170 anticipate submitting the results of this scoping review for publications in March 2023.

171 **Methods**

172 Scoping reviews differ from systematic reviews in that they focus on reviewing the
173 breadth, rather than depth of current literature regarding a particular topic. For this reason, they
174 may be completed much more rapidly than systematic reviews, which take time to assess the
175 quality of evidence among studies. A scoping review was chosen to quickly ascertain the nature

176 of the knowledge base surrounding factors that influence culturally responsive HIV and PrEP
177 screening for patients identifying as members of minoritized groups.

178 The scoping review will be performed according to the framework first outlined by
179 Arksey and O'Malley.¹³ The five steps of this process include: 1) identifying a research question,
180 2) identifying relevant studies, 3) selecting studies, 4) charting the data, and 5) collating,
181 summarizing, and reporting the results. This will also be guided by the specific steps of the
182 PRISMA extension for scoping reviews (PRISMA-ScR),¹⁴ several of which will be described in
183 relevant sections below.

184 **Step 1: Identifying a research question**

185 The primary research question (PRISMA-ScR Item 4: Objectives) in this review will be,
186 “*what factors influence culturally responsive HIV and PrEP screening for historically*
187 *marginalized populations?*” to explore the ways we might disrupt structures of power working
188 against patients from minoritized groups. A secondary question will be, “*what themes and gaps*
189 *exist in the literature regarding culturally responsive HIV and PrEP screening for historically*
190 *marginalized populations?*” to identify areas of interest for future research.

191 **Step 2: Identifying relevant studies**

192 The scoping review will be conducted across four databases (PRISMA-ScR Item 7:
193 Information Sources): MEDLINE (PubMed), Scopus, Cochrane (CENTRAL; Wiley), and
194 CINAHL (EBSCO). The search strategy includes the use of Medical Subject Headings (MeSH)
195 terms and Boolean terms to clarify the parameters of the review. After conducting the searches
196 on each database, the results will be imported into Covidence to remove duplicates and perform

197 primary screening of titles and abstracts for relevance. The full search strategy (PRISMA-ScR

198 Item 8: Search) is presented in Table 1.

199 *Table 1: Search Terms and Limitations*

| Database | Search Terms | Limitations |
|----------|---|--|
| MEDLINE | <p>(marginalized [tiab] OR health services for transgender persons [mesh] OR health services for transgender persons [tiab] OR LGBT* [tiab] OR sexual and gender minorities [mesh] OR sexual minorit* [tiab] OR gender minorit* [tiab] OR lesbian* [tiab] OR WSW [tiab] OR women who have sex with women [tiab] OR gay [tiab] OR gays [tiab] OR MSM [tiab] OR BMSM [tiab] OR YMSM [tiab] OR men who have sex with men [tiab] OR homosexuality [mesh] OR homosexual* [tiab] OR bisexual* [tiab] OR queer* [tiab] OR nonbinary [tiab] OR intersex [tiab] OR transgender [tiab] OR transgender persons [mesh] OR minority groups [mesh] OR minorit* [tiab] OR health disparity, minority and vulnerable populations [mesh] OR ethnic and racial minorities [mesh] OR ethnic minorit* [tiab] OR racial minorit* [tiab] OR BIPOC [tiab] OR POC [tiab] OR people of color [tiab] OR black* [tiab] OR blacks [mesh] OR african americans [mesh] OR african american* [tiab] OR indigenous peoples [mesh] OR indigenous [tiab] OR health services, indigenous [mesh] OR native* [tiab] OR nation people* [tiab] OR american native continental ancestry group [mesh] OR indian* [tiab] OR inuits [mesh] OR inuit* [tiab] OR hispanic* [tiab] OR hispanic or latino [mesh] OR latin* [tiab] OR asians [mesh] OR asian* [tiab] OR asian americans [mesh] OR native hawaiian or other pacific islander [mesh] OR pacific islander* [tiab])</p> <p>AND</p> <p>(cultural* responsi* [tiab] culturally-responsive [tiab] OR culturally competent care [mesh] OR cultural* competen* [tiab] OR cultural* aware* [tiab] OR culturally-aware [tiab] OR cultural* sensitiv* [tiab] OR culturally-sensitive [tiab] OR cultural* congruen* [tiab] OR culturally-congruent [tiab] OR cross-cultur* [tiab] OR cultural* grounded* [tiab] OR inclusi* [tiab] OR competen* [tiab] OR cultural* adapt* [tiab] OR</p> | <p>English language</p> <p>2019-2022 publication years</p> |

| | | |
|--------|---|--|
| | <p>culturally-adapted [tiab] OR cultural* tailor* [tiab] OR culturally-tailored [tiab] OR culturally influenced [tiab] OR affirm* [tiab] OR transcultural [tiab] OR multicultural [tiab] OR intercultural [tiab] OR cultural* litera* [tiab] OR cultural* respect* [tiab] OR cultural* appropriate* [tiab] OR cultural* accept* [tiab] OR cultural* safe* [tiab] OR cultural* intelligen* [tiab])</p> <p>AND</p> <p>(HIV [mesh] OR HIV [tiab] OR human immunodeficiency virus [tiab] OR HIV infections [mesh] OR AIDS [tiab] OR acquired immunodeficiency syndrome [mesh] OR acquired immunodeficiency syndrome [tiab])</p> <p>AND</p> <p>(screen* [tiab] OR mass screening [mesh] OR detect* [tiab] OR testing [tiab] OR diagnosis [mesh] OR diagnos* [tiab] OR prep [tiab] OR prevention [tiab] OR prevention [mesh] OR pre-exposure [tiab] OR pre [tiab])</p> | |
| Scopus | <p>(TITLE-ABS-KEY (marginalized) OR TITLE-ABS-KEY ("health services for transgender persons") OR TITLE-ABS-KEY (LGBT*) OR TITLE-ABS-KEY ("sexual minorit*") OR TITLE-ABS-KEY ("gender minorit*") OR TITLE-ABS-KEY (lesbian*) OR TITLE-ABS-KEY (WSW) OR TITLE-ABS-KEY ("women who have sex with women") OR TITLE-ABS-KEY (gay) OR TITLE-ABS-KEY (gays) OR TITLE-ABS-KEY (MSM) OR TITLE-ABS-KEY (BMSM) OR TITLE-ABS-KEY (YMSM) OR TITLE-ABS-KEY ("men who have sex with men") OR TITLE-ABS-KEY (homosexual*) OR TITLE-ABS-KEY (bisexual*) OR TITLE-ABS-KEY (queer*) OR TITLE-ABS-KEY (nonbinary) OR TITLE-ABS-KEY (intersex) OR TITLE-ABS-KEY (transgender) OR TITLE-ABS-KEY (minorit*) OR TITLE-ABS-KEY ("ethnic minorit*") OR TITLE-ABS-KEY ("racial minorit*") OR TITLE-ABS-KEY (BIPOC) OR TITLE-ABS-KEY (POC) OR TITLE-ABS-KEY ("people of color") OR TITLE-ABS-KEY (black*) OR TITLE-ABS-KEY ("african american*") OR TITLE-ABS-KEY (indigenous) OR TITLE-ABS-KEY (native*) OR TITLE-ABS-KEY ("nation people*") OR TITLE-ABS-KEY (indian*) OR TITLE-ABS-KEY (inuit*) OR TITLE-ABS-KEY (hispanic*) OR TITLE-ABS-KEY (latin*) OR TITLE-ABS-KEY (asian*))</p> | <p>English language</p> <p>2019-2022 publication years</p> |

| | | |
|---------------------------|--|--|
| | <p>OR TITLE-ABS-KEY (“pacific islander**”)</p> <p>AND</p> <p>(TITLE-ABS-KEY (“cultural* responsi**”) OR TITLE-ABS-KEY (“cultural* competen**”) OR TITLE-ABS-KEY (“cultural* aware**”) OR TITLE-ABS-KEY (“cultural* sensitiv**”) OR TITLE-ABS-KEY (“cultural* congruen**”) OR TITLE-ABS-KEY (cross-cultur*) OR TITLE-ABS-KEY (“cultural* grounded**”) OR TITLE-ABS-KEY (inclusi*) OR TITLE-ABS-KEY (competen*) OR TITLE-ABS-KEY (“cultural* adapt**”) OR TITLE-ABS-KEY (“cultural* tailor**”) OR TITLE-ABS-KEY (“culturally influenced”) OR TITLE-ABS-KEY (affirm*) OR TITLE-ABS-KEY (transcultural) OR TITLE-ABS-KEY (multicultural) OR TITLE-ABS-KEY (intercultural) OR TITLE-ABS-KEY (“cultural* litera**”) OR TITLE-ABS-KEY (“cultural* respect**”) OR TITLE-ABS-KEY (“cultural* appropriate**”) OR TITLE-ABS-KEY (“cultural* accept**”) OR TITLE-ABS-KEY (“cultural* safe**”) OR TITLE-ABS-KEY (“cultural* intelligen**”))</p> <p>AND</p> <p>(TITLE-ABS-KEY (HIV) OR TITLE-ABS-KEY (“human immunodeficiency virus”) OR TITLE-ABS-KEY (AIDS) OR TITLE-ABS-KEY (“acquired immunodeficiency syndrome”))</p> <p>AND</p> <p>(TITLE-ABS-KEY (screen*) OR TITLE-ABS-KEY (detect*) OR TITLE-ABS-KEY (testing) OR TITLE-ABS-KEY (diagnos*))</p> | |
| <p>Cochrane (CENTRAL)</p> | <p>((marginalized) OR (“health services for transgender persons”) OR (LGBT*) OR (“sexual minorit**”) OR (“gender minorit**”) OR (lesbian*) OR (WSW) OR (“women who have sex with women”) OR (gay) OR (gays) OR (MSM) OR (BMSM) OR (YMSM) OR (“men who have sex with men”) OR (homosexual*) OR (bisexual*) OR (queer*) OR (nonbinary) OR (intersex) OR (transgender) OR (minorit*) OR (“ethnic minorit**”) OR (“racial minorit**”) OR (BIPOC) OR (POC) OR (“people of color”) OR (black*) OR (“african american**”) OR (indigenous) OR (native*) OR (“nation people**”) OR (indian*) OR (inuit*) OR (hispanic*) OR (latin*) OR (asian*) OR (“pacific islander**”))</p> <p>AND</p> <p>((“cultural* responsi**”) OR (“cultural* competen**”) OR</p> | <p>English language</p> <p>2019-2022 publication years</p> |

| | | |
|--------|--|--|
| | <p>(“cultural* aware*”) OR (“cultural* sensitiv*”) OR (“cultural* congruen*”) OR (cross-cultur*) OR (“cultural* grounded*”) OR (inclusi*) OR (competen*) OR (“cultural* adapt*”) OR (“culturally adapted”) OR (“cultural* tailor*”) OR (affirm*) OR (transcultural) OR (multicultural) OR (intercultural) OR (“cultural* litera*”) OR (“cultural* respect*”) OR (“cultural* appropriate*”) OR (“cultural* accept*”) OR (“cultural* safe*”) OR (“cultural* intelligen*”)</p> <p>AND</p> <p>((HIV) OR (“human immunodeficiency virus”) OR (AIDS) OR (“acquired immunodeficiency syndrome”)</p> <p>AND</p> <p>((screen*) OR (detect*) OR (testing) OR (diagnos*))</p> | |
| CINAHL | <p>(SU (marginalized OR health services for transgender persons OR LGBT* OR sexual minorit* OR gender minorit* OR lesbian* OR WSW OR women who have sex with women OR gay OR gays OR MSM OR BMSM OR YMSM OR men who have sex with men OR homosexual* OR bisexual* OR queer* OR nonbinary OR intersex OR transgender OR minorit* OR ethnic minorit* OR racial minorit* OR BIPOC OR POC OR people of color OR black* OR african american* OR indigenous OR native* OR nation people* OR indian* OR inuit* OR hispanic* OR latin* OR asian* OR pacific islander*) OR TI (marginalized OR health services for transgender persons OR LGBT* OR sexual minorit* OR gender minorit* OR lesbian* OR WSW OR women who have sex with women OR gay OR gays OR MSM OR BMSM OR YMSM OR men who have sex with men OR homosexual* OR bisexual* OR queer* OR nonbinary OR intersex OR transgender OR minorit* OR ethnic minorit* OR racial minorit* OR BIPOC OR POC OR people of color OR black* OR african american* OR indigenous OR native* OR nation people* OR indian* OR inuit* OR hispanic* OR latin* OR asian* OR pacific islander*) OR AB (marginalized OR health services for transgender persons OR LGBT* OR sexual minorit* OR gender minorit* OR lesbian* OR WSW OR women who have sex with women OR gay OR gays OR MSM OR BMSM OR YMSM OR men who have sex with men OR homosexual* OR bisexual* OR queer* OR nonbinary OR intersex OR transgender OR minorit* OR ethnic minorit* OR racial minorit* OR BIPOC OR POC OR people of</p> | <p>English language</p> <p>2019-2022 publication years</p> |

| | | |
|--|--|--|
| | <p>color OR black* OR african american* OR indigenous OR native* OR nation people* OR indian* OR inuit* OR hispanic* OR latin* OR asian* OR pacific islander*) OR MH (sexual and gender minorities OR indigenous peoples OR hispanic americans OR asians OR black persons))</p> | |
| | <p>AND</p> | |
| | <p>(SU (cultural* responsi* OR cultural* competen* OR cultural* aware* OR cultural* sensitiv* OR cultural* congruen* OR cross-cultur* OR cultural* grounded* OR inclusi* OR competen* OR cultural* adapt* OR cultural* tailor* OR culturally influenced OR affirm* OR transcultural OR multicultural OR intercultural OR cultural* litera* OR cultural* respect* OR cultural* appropriate* OR cultural* accept* OR cultural* safe* OR cultural* intelligen*) OR TI (cultural* responsi* OR cultural* competen* OR cultural* aware* OR cultural* sensitiv* OR cultural* congruen* OR cross-cultur* OR cultural* grounded* OR inclusi* OR competen* OR cultural* adapt* OR cultural* tailor* OR culturally influenced OR affirm* OR transcultural OR multicultural OR intercultural OR cultural* litera* OR cultural* respect* OR cultural* appropriate* OR cultural* accept* OR cultural* safe* OR cultural* intelligen*) OR AB (cultural* responsi* OR cultural* competen* OR cultural* aware* OR cultural* sensitiv* OR (cultural* congruen* OR cross-cultur* OR cultural* grounded* OR inclusi* OR competen* OR cultural* adapt* OR cultural* tailor* OR culturally influenced OR affirm* OR transcultural OR multicultural OR intercultural OR cultural* litera* OR cultural* respect* OR cultural* appropriate* OR cultural* accept* OR cultural* safe* OR cultural* intelligen*) OR MH (cultural competence OR transcultural care))</p> | |
| | <p>AND</p> | |
| | <p>(SU (HIV OR human immunodeficiency virus OR AIDS OR acquired immunodeficiency syndrome) OR TI (HIV OR human immunodeficiency virus OR AIDS OR acquired immunodeficiency syndrome) OR AB (HIV OR human immunodeficiency virus OR AIDS OR acquired immunodeficiency syndrome) OR MH (human immunodeficiency virus OR acquired immunodeficiency syndrome))</p> | |
| | <p>AND</p> | |

| | | |
|--|---|--|
| | (SU (screen* OR detect* OR testing OR diagnos*) OR TI (screen* OR detect* OR testing OR diagnos*) OR AB (detect* OR testing OR diagnos*) OR MH (diagnosis OR health screening)) | |
|--|---|--|

200 **Step 3: Selecting Studies**

201 **Inclusion Criteria**

202 The search will be limited (PRISMA-ScR Item 6: Eligibility Criteria) to studies that
203 concern screening services, specifically regarding HIV and/or PrEP. In addition to the search
204 strategy delineated above (**Table 1**), studies will be included in the review if they meet the
205 following inclusion criteria:

- 206 Published, peer-reviewed research articles
- 207 Studies published in English
- 208 Studies that consider data collected in the U.S./in the context of U.S. health
209 systems

210 **Exclusion Criteria**

211 Studies that meet the following exclusion criteria will be excluded from the review:

- 212 Studies where the team cannot obtain full-text articles
- 213 Book chapters and study protocols
- 214 Studies published in a language other than English
- 215 Studies published prior to 2019
- 216 Data collected from any country other than the U.S., except for systematic
217 reviews

218 ☐ Studies that do not address one or more of our historically marginalized
219 populations of interest or studies that do not discuss people of unknown or
220 negative HIV status

221 Results will be limited to published, peer-reviewed studies to create a standard for
222 included articles, as they will not be assessed for quality of evidence. Results must have been
223 published in English, as the team does not have the resources to translate foreign language
224 studies. Further, since our training intervention seeks to improve outcomes among patients in the
225 U.S. by understanding barriers and facilitators among U.S.-based PCPs, results will be limited to
226 studies that were conducted in the U.S. or that concern U.S. health systems. Study protocols will
227 be excluded because they are not predicted to be of use, and book chapters will be excluded to
228 avoid the use of non-peer-reviewed materials. Since the intervention ultimately informed by this
229 scoping review is two-pronged and targets both HIV and COVID-19 screening, included studies
230 will be limited to those published between the years 2019-2022 (mirroring the timeline of the
231 COVID-19 pandemic), rather than including HIV-related research from the past four decades.
232 Finally, since this review will inform interventions regarding HIV and/or PrEP screening for
233 patients from racial, ethnic, sexual, and gender minority backgrounds, studies must focus on at
234 least one of these groups, and must include. Articles will necessarily be limited to those that
235 include individuals of negative or unknown HIV status, because these are the patients who are
236 eligible to be screened for HIV and PrEP.

237 Results will be uploaded to Covidence, a screening and data extraction tool, to eliminate
238 duplicate studies, followed by two stages of screening: a title/abstract screening, followed by a
239 full-text screening (PRISMA-ScR Item 9: Selection of Sources of Evidence). The primary
240 reviewers (JX, NK) will screen all the results against the inclusion and exclusion criteria and

241 must agree to include or exclude a study to make a decision. Senior reviewers (PM and PC) will
242 resolve disagreements. After completing the title/abstract screening, reviewers (JX, NK, SP, DB)
243 will perform a full-text screening on the remaining studies and further eliminate irrelevant
244 studies, and PM and PC will provide guidance and reconciliation as required. To assess interrater
245 reliability, all reviewers will informally screen the same several articles at the start of both
246 title/abstract screening and full-text screening phases and come together to discuss the
247 criteria/process used to include or exclude studies.

248 **Step 4: Charting the data**

249 After studies have undergone a full-text screening, data will be extracted and charted by
250 nine reviewers (JX, NK, SP, DB, SS, PC, AK, MW, PM) (PRISMA-ScR Item 10: Data Charting
251 Process). The data items for extraction (PRISMA-ScR Item 11: Data Items) were developed
252 through an iterative process that consulted team members and created a working definition of
253 each item to streamline the extraction process. Checkboxes were chosen over text fields for
254 several items to minimize variability among different reviewer inputs. The data that will be
255 charted includes:

- 256 Reviewer
- 257 Covidence ID
- 258 Author(s)
- 259 Publication title
- 260 Publication year
- 261 Study location
- 262 Study design
- 263 Intervention type

- 264 ☐ Timeframe of study
- 265 ☐ Study aims
- 266 ☐ Study population
- 267 ☐ Methodology overview
- 268 ☐ Measures
- 269 ☐ Results
- 270 ☐ Level of communication addressed
- 271 ☐ How does it address Black Indigenous, and People of Color (BIPOC) groups?
- 272 ☐ How does it address lesbian, gay, bisexual, transgender, queer/questioning, intersex, and
- 273 asexual (LGBTQIA+) groups?
- 274 ☐ What aspects of cultural responsiveness are addressed?
- 275 ☐ Facilitators to culturally responsive communication identified
- 276 ☐ Barriers to culturally responsive communication identified
- 277 ☐ Implications
- 278 ☐ What is left unanswered?
- 279 ☐ Limitations or biases

280 **Results**

281 **Step 5: Collating, summarizing, and reporting the results**

282 After extraction, reviewers will quantify mentions of specific barriers and facilitators to
283 identify their prevalence, then pull quotations from each included study to describe each
284 identified influence. The implications extracted from each study will be analyzed for themes
285 related to culturally responsive HIV and PrEP screening practices for historically marginalized
286 populations. The data will be reviewed to identify how each study contributes to our

287 understanding of the primary research question. Additionally, the review will identify any gaps
288 in existing literature and opportunities for future research in this field. This analysis will not
289 include a systematic evaluation of study quality or risk of bias, because this scoping review aims
290 to focus on the scope and breadth, rather than the quality of available literature. After analysis,
291 results will be synthesized and reported according to PRISMA-ScR guidelines (Item 13:
292 Synthesis of Results; Items 15-19), and the process used to select studies will be detailed in a
293 PRISMA flowchart (PRISMA-ScR Item 14: Selection of Sources of Evidence).

294 **Discussion**

295 Culturally responsive HIV screening conversations between PCPs and minoritized groups
296 are key to bridging the stark existing disparities in HIV morbidity and mortality in the U.S. To
297 our knowledge, this is the first study to use scoping methods to investigate the barriers and
298 facilitators to culturally responsive HIV and PrEP screening for minoritized populations. After
299 mapping the landscape, gaps, and themes of current research, we plan to disseminate our
300 findings in publication and through the development of relevant and evidence-based training
301 programs to help PCPs routinize culturally responsive HIV and PrEP screening for minoritized
302 groups. Additionally, we anticipate that this study will yield implications important to the work
303 of activists, researchers, patients, and public health professionals in this field. The limitations of
304 this study include that as a scoping review, our review does not assess the depth, quality, or risk
305 of bias of the studies the way a systematic review would. Additionally, by limiting the timeline
306 of this review to the years 2019-2022, we may miss valuable studies that were performed before
307 this timeframe.

308

309

310 **Funding**

311 Funding made available by Gilead Sciences Inc.

312

313 **Institutional Review Board Statement**

314 This project did not utilize human subjects, was exempted from needing IRB approval, and
315 therefore did not involve a process of informed consent. This manuscript exclusively provides an
316 overview of a scoping review protocol. The data from this scoping review will be used to inform
317 and strengthen an educational intervention that will be IRB-approved and supported by grant
318 funding.

319

320 **Conflict of Interest**

321 The authors declare no conflict of interest.

322

323 **Acknowledgments**

324 The authors would like to acknowledge Thomas Harrod, Associate Director of Reference,
325 Instruction, and Access at the George Washington University's Himmelfarb Health Sciences
326 Library for his generous guidance and support in developing the search strategies for this scoping
327 review and Stacy Brody, Reference and Instruction Librarian at the George Washington
328 University's Himmelfarb Health Sciences Library for her guidance in creating the manuscript for
329 this publication. The authors would like to acknowledge Saylor Pershing, Darrell Bailey, Sheel
330 Singh, and Abigail Konopasky for their assistance in the text screening and extraction process.

331

References

- 332
- 333
- 334
- 335
- 336
- 337
- 338
- 339
- 340
- 341
- 342
- 343
- 344
- 345
- 346
- 347
- 348
- 349
- 350
- 351
- 352
- 353
1. Tucker CM, Marsiske M, Rice KG, Nielson JJ, Herman K. Patient-centered culturally sensitive health care: Model testing and refinement. *Health Psychology*. 2011;30(3):342-350. doi:10.1037/a0022967
 2. Cultural competence in Health and Human Services. NPIN. <https://npin.cdc.gov/pages/cultural-competence>. Accessed December 2, 2022.
 3. Brown L, Spinelli M, Gandhi M. The interplay between HIV and COVID-19: Summary of the data and responses to date. *Current Opinion in HIV and AIDS*. 2021; 16 (1): 63-73. doi: 10.1097/COH.0000000000000659.
 4. Basic statistics | HIV basics | HIV/AIDS. CDC. <https://www.cdc.gov/hiv/basics/statistics.html>. Published June 21, 2022. Accessed December 2, 2022.
 5. *HIV infection, risk, prevention, and testing behaviors among transgender women—National HIV behavioral surveillance, 7 U.S. cities, 2019–2020*. CDC; 2021. <https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>.
 6. U. S. census bureau quickfacts: United States. <https://www.census.gov/quickfacts/fact/table/US/PST045221>. Accessed December 2, 2022.
 7. U. S. statistics. HIV.gov. <https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics>. Accessed December 2, 2022.
 8. Ending the HIV epidemic | Overview. HIV.gov. <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. Accessed December 2, 2022.

- 354 9. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2021
355 update: A clinical practice guideline. CDC. [https://www.cdc.gov/hiv/pdf/risk/prep/cdc-](https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf)
356 [hiv-prep-guidelines-2021.pdf](https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf). Published December 8, 2021. Accessed December 28,
357 2022
- 358 10. Monitoring selected national HIV prevention and care objectives by using HIV
359 surveillance data United States and 6 dependent areas, 2020. CDC.
360 <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-27-no-3/index.html>.
361 Published August 26, 2022. Accessed December 2, 2022.
- 362 11. Branson BM, Handsfield HH, Lampe MA, et al. *Revised recommendations for HIV*
363 *testing of adults, adolescents, and pregnant women in health-care settings*. MMWR
364 2006; 55(RR14);1-17. <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm>.
365 Accessed December 1, 2022.
- 366 12. Hoover KW, Huang YA, Tanner ML, et al. *HIV testing trends at visits to physician*
367 *offices, community health centers, and emergency departments — United States, 2009–*
368 *2017*. MMWR 2020; 69(25):776-780. doi:10.15585/mmwr.mm6925a2
- 369 13. Arksey H, O’Malley L. Scoping studies: Towards a methodological framework.
370 *International Journal of Social Research Methodology*. 2005;8(1):19-32.
371 doi:10.1080/1364557032000119616
- 372 14. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-
373 ScR): Checklist and explanation. *Ann Intern Med*. 2018;169(7):467-473.
374 doi:10.7326/M18-0850